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stratified according to planned GPllb/llla inhibitor use. Bolus Dalt. or UFH were 
administered via arterial sheath (100 units/kg alone or 70units/kg with planned GP) 
immediately prior to PCI. The primary endpoint was death, myocardial infarction (defined 
as CK-MB&?XULN). urgent CABGlPCl or need for bail-out GP) up to 24 hours post-pro- 
cedure. 
Results: A total of 321 (Dan. 160 (51 planned GP) vs UFH 161 (50 planned GP) patients 
were randomized. All randomized patients received the assigned drug and underwent 
PCI. Overall baseline characteristics were as follows: mean age 62.9 yrs. male gender 
70.4%. diabetes 25.5%. PCI post acute coronary syndrome 50.5%, stent 88.2%, multi- 
vessel 11.5%, ad-hoc PCI 27.1%, clopidogrel pretreatment 87%. The primary endpoint 
was reached in 21(13.1%) Dalt. and 22(13.7%) UFH patients (p=ns). There was one 
death in the Dalt. group due to guider dissection. Angiographic complications (abrupt clo- 
sure or new thrombus) occurred in 6 (3.8%) Dalt. YS 4(2.5%) UFH patients. There were 
two major bleeds, both in the UFH group. The primary composite plus rehospitalization 
at 30 days was 18.1% vs 16.1%, Dalt. vs UFH patients. Mean activated clotting time at 
30 minutes post bolus was 239s for Dalt. YS 345s for UFH. Mean anti-factor Xa levels 
were Dalt. 1.1 dmLvs UFH 0.8 u/mLat 30 minutes and Dalt.0.6 u/mLvs UFH 0.2 u/mL at 
4 hours post PCI. Conclusions: Dalt. appears to be a safe and effective alternative to 
UFH during PCI, either alone or in combination with IV GPllblllla inhibitors. Despite ele- 
vated anti-factor Xa levels at 4 hours, bleeding complications were not increased III the 
Dalt. group. 
1176-202 Tissue Factor Predicts Long-Term Outcome After 
Percutaneous Coronary Revaecularization 
Sophie Susen. Karine Sautiere, Christophe Zawadzki, Anne Bauters, Jean Dallongeville. 
Philippe Asseman, Christophe Bauters, Jean Marc Lablanche, Brigitte Jude, Eric Van 
Belle, Hapital Cardiologique, Lille, France, lnstitut Pasteur, Lille, France 
Background:Tissue factor (TF) induced upon inflammatory stimuli including C-reactive 
protein (CRP) could participate in the thrombus progression associated with plaque rup- 
ture. 
The aim of this study was to determine the predictive value of plasma levels of TF mea- 
sured immediately before percutaneous coronary revascularization (PCR). 
Methods:Plasma TF and hs CRP were prospectively measured in 175 consecutive 
patients before PCR. Patients with 1.5 nglmL were excluded. The primary endpoint was 
the composite of death, myocardial infarction and hospitalization for unstable angina at 
one year. Multivariate correlates of events were analyzed with the use of Cox’s propor- 
tional hazard model. Risk factors such as age, gender, diabetes. smoking status, family 
history of CAD, hypertension, hyperlypidemia, unstable angina, left ventricular ejection 
fraction, hs CRP and plasma TF were included in the analysis. 
Results: The mean +/- SD TF level was 205 +/- 169 pg/mL and the mean +/- SD hs CRP 
level was 0.8+/- 1.6 mg/dL. The actuarial rate of events was 9.7% at 1 year. Tertiles of 
TF were predictors of cardiac events at 1 year (see Table). 
Three independent predictors were found in this population: diabetes (p=O.O07), hs CRP 
(p=O.Ol) and plasma TF (p=O.O2). 
Conclusion: Plasma TF measured immediately before PCR is an independent predictor 
of cardiac events at 1 year. This suggests that measurement of TF may help to select 
patients at high risk of events following PCR. 
n events (%) 
tertile 1 (<I30 pg/mL) 60 1.7% 
tertile 2 59 8.5% 
terlile 3 (>POOpg/mL) 56 19.6% 
0.005 
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Background: Angiographlc In-stent pattern (ISRP) is an important predictor of RS after 
conventional PCI. The prognostic value of ISRP after gamma VBT has not been defined. 
Methods : From a pooled data set of gamma VBT for ISR trials, the ISRP was assessed 
in 531 pts. Placebo (N=206) and radiated (N=327) pts were compared for angiographic 
recurrence based on the ISRP. The patterns are defined as focal (I), diffuse in stent (II), 
diffuse proliferative (Ill) or total occlusion (IV). 
Results Demographics were well matched between groups. Mean reference diameter 
(2.66kO.6 vs 2.67t0.5), lesion length (22.7ill.8 YS 21.2+11) and final MLD (1.99+0.4 vs 
1.95e 0.3) were similar (p=NS) between placebo and radiated patients. Angiographic RS 
rate increased with higher ISRP class for placebo (42.2%, 63.6%. 79.3%. 69.2%, 
p=O.O02) and radiated pts (l&7%, 31.6%, 43.1%. 80%, pcO.001) from I to IV, respec- 
tively (graphic). A treatment effect was maintained with Gamma VBT except for ISRP IV, 
where RS rate was not significantly different compared to placebo. By multivanable 
regression analysis, ISRP was an independent predictor of treated segment RS in both 
treatment groups. 
Conclusions : Angiographic classification of ISR is prognostically important independent 
of the treatment applied. Although a treatment effect is observed in class I, II and Ill, 
gamma radiation does not improve angiographic outcome in pattern IV compared to pla- 
cebo. ISRP continues to identify pts with higher probability of recurrence even after 
Gamma VBT. 
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Background:The Washington Radiation for In-Stent Restenosis Trial (WRIST) is a dou- 
ble-blinded randomized study evaluating the effects of intracoronary radiation therapy 
(IRT) in patients (pts) with in-stent restenosis (ISR). 
Methods: One hundred and thirty pts with ISR (100 native coronary and 30 vein grafts) 
underwent PTCA. laser ablation, rotational atherectomy, and/or additional stating (36% 
of lesions). Pts were randomized to either’92 II IRT. with a prescribed dose of 15 Gy to a 
2 mm radial distance from the center of the source or to placebo. 
Results: Angiographic restenosis (27% vs. 56%, p=O.O02) and target vessel revascular- 
ization (TVR. (26% vs. 66%, pcO.OOl)] were dramatically reduced at 6 months in IRT pts. 
Between 6 and 60 months, IRT pts compared to placebo had more target lesion revascu- 
larization (IRT=20% vs. placebo=l.5%. p=O.OOl) and TVR (IRT=20% vs. placebo=3%, 
p=O.O03). At 60 months clinical follow-up, pts receiving IRT continued to have markedly 
lower MACE (TLR) rates when compared with placebo: 51% vs.71%, p=O.O2 (see Fig- 
ure). 
Conclusions: In WRIST, pts with ISR treated with IRT using “‘lr had a marked reduc- 
tion in the need for repeat target lesion and vessel revascularization at 6 months. 
Although more events were recorded in the irradiated group at the follow-up 6-60 
months, the clinical benefit was maintained at five years without adverse events related 
to the radiation therapy 
